Skip to main content

Free Content Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Summary Objectives  To examine whether the humoural response to malaria vaccine candidate antigens, [circumsporozoite repetitive sequence (NANP) GLURP fragments (R0 and R2) and MSP3] varies with the level of malaria transmission and to determine whether the antibodies (IgG) present at the beginning of the malaria transmission season protect against clinical malaria. Methods  Cross-sectional surveys were conducted to measure antibody response before, at the peak and at the end of the transmission season in children aged 6 months to 10 years in two villages with different levels of malaria transmission. A cohort study was performed to estimate the incidence of clinical malaria. Results  Antibodies to these antigens showed different seasonal patterns. IgG concentrations to any of the four antigens were higher in the village with high entomological inoculation rate. Multivariate analysis of combined data from the two villages indicated that children who were classified as responders to the selected antigens were at lower risk of clinical malaria than children classified as non-responders [(NANP) (incidence rate ratio (IRR) = 0.65, 95% CI: 0.46–0.92;  = 0.016), R0 (IRR = 0.69, 95% CI: 0.48–0.97;  = 0.032), R2 (IRR = 0.73, 95% CI: 0.50–1.06;  = 0.09), MSP3 (IRR = 0.52, 95% CI: 0.32–0.85;  = 0.009)]. Fitting a model with all four antibody responses showed that MSP3 looked the best malaria vaccine candidate (IRR = 0.63; 95% CI: 0.38–1.05;  = 0.08). Conclusion  Antibody levels to the four antigens are affected by the intensity of malaria transmission and associated with protection against clinical malaria. It is worthwhile investing in the development of these antigens as potential malaria vaccine candidates.


Examiner si la réponse humorale aux antigènes de candidats vaccins de la malaria, P. falciparum (séquence répétitive de la circumsporozoïte (NANP)5, fragments GLURP (R0 et R2) et MSP3) varie avec le taux de la transmission de la malaria et déterminer si les anticorps (IgG) présents au début de la saison de transmission de la malaria protègent contre la malaria clinique. Méthodes 

Etudes transversales pour mesurer la réponse d’anticorps avant, au pic et à la fin de la saison de transmission chez les enfants âgés de 6 mois à 10 ans dans deux villages avec des taux différents de transmission de malaria. Une étude de cohorte a été réalisée pour estimer l’incidence de la malaria clinique. Résultats 

Les anticorps correspondant à ces antigènes montraient différents profils saisonniers. Les taux d’IgG correspondant à chacun des quatre antigènes étaient plus élevés dans le village ayant un taux élevé d’inoculation entomologique. L’analyse multivariée des données combinées des deux villages a indiqué que les enfants classifiés comme répondants aux antigènes sélectionnés avaient un risque inférieur de malaria clinique par rapport à ceux classifiés comme non-répondants [(NANP)5 (IRR = 0,65, IC95%: 0,46–0,92; P = 0,016), R0 (IRR = 0,69, IC95%: 0,48–0,97; P = 0,032), R2 (IRR = 0,73, IC95%: 0,50–1,06; P = 0,09), MSP3 (IRR = 0,52, IC95%: 0,32–0,85; P = 0,009)]. Un modèle incorporant chacune des quatre réponses d’anticorps a démontré que MSP3 était le meilleur candidat vaccin contre la malaria (IRR = 0,63; IC95%: 0,38–1,05; P = 0,08). Conclusion 

Les taux d’anticorps correspondant aux quatre antigènes sont affectés par l’intensité de la transmission de malaria et associés à la protection contre la malaria clinique. Il serait intéressant d’investir dans le développement de ces antigènes en tant que candidats vaccins potentiels contre la malaria.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Malaria; antibody response; antigènes de candidats vaccins; antígenos candidatos a vacuna; intensidad de transmisión; intensité de transmission; malaria; respuesta de anticuerpos; réponse d’anticorps; transmission intensity; vaccine candidate antigens

Document Type: Research Article

Affiliations: 1:  Centre National de Recherche et de Formation sur le paludisme, Ouagadougou, Burkina Faso 2:  Department of Microbiology and Biochemistry, University of Ouagadougou, Ouagadougou, Burkina Faso 3:  Department of Clinical Biochemistry Statens Serum, Copenhagen, Denmark 4:  Institute of Biochemistry, University of Lausanna, Lausanna, Switzerland 5:  Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

Publication date: 01 February 2008

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more